The Safety and Efficacy of Absnow Fully Biodegradable Atrial Septal Defect Occluder: A Prospective, Single-Center
Shiqiang Fan1, Ying Xie1, Zhenheng Ou1
1Department of Cardiology, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
Objective:
To evaluate the safety, short-term and mid-term occlusion performance of the Absnow fully biodegradable atrial septal occluder in pediatric patients.
Background:
The Absnow Occluder, an innovative fully biodegradable closure for ASD, has shown its safety and effectiveness in initial animal studies and preclinical trials.
Methods:
As one of the participating multicenter research institutions, our organization conducted interventional closure procedures on 10 pediatric patients with atrial septal defects employing the Absnow fully biodegradable occluder between November 2018 and May 2019. Subsequently, we conducted a clinical follow-up spanning 4 years.
Results:
The immediate success rate of the operation was 100% (10/10). The effective closure rates at immediate, 1 day, 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, and 4 years post-operation were, respectively, 100%, 90%, 100%, 100%, 100%, 100%, 80%, 80%, and 70%. The cumulative incidence of complications at 1 year, 2 years, 3 years, and 4 years post-operation were 0%, 20%, 20%, and 30%, respectively. No severe complications, such as device dislodgment, high-degree atrioventricular block, or vascular complications, occurred during the 4-year follow-up. Nevertheless, two patients experienced substantial residual shunting due to occluder degradation or umbrella displacement, and underwent further intervention.
Conclusion:
This study further confirmed the short-to-mid-term safety and acceptable efficacy of the Absnow fully biodegradable atrial septal occluder based on a 4-year follow-up. The late-occurring residual shunts with device degradation have an important impact on its long-term efficacy.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
01:28Inductance: Single-Phase And Three-Phase Line
Single-Phase Two-Wire Line:
A single-phase line consists of two solid cylindrical conductors, denoted as x and y. Each conductor carries phasor currents ix and iy, respectively. Given that the sum of these currents is...
01:25Capacitance: Single-Phase And Three-Phase Line
Single-Phase Lines
Consider a single-phase, two-wire transmission line with equal phase spacing energized by a voltage source. One conductor carries a uniform positive charge, while the other carries an equal negative charge. The capacitance C of the line can be derived from the voltage V between the conductors. For a one-meter section of the line, the capacitance is given...
01:12Statistical Software for Data Analysis and Clinical Trials
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...